A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo

In vivo genome editing using Staphylococcus aureus Cas9

Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687 · see citing works

Biology and Applications of CRISPR Systems: Harnessing Nature’s Toolbox for Genome Engineering

Wright, A. V., Nuñez, J. K., & Doudna, J. A. (2016) · Cell · doi:10.1016/j.cell.2015.12.035 · Cited by 1,001 · see citing works

HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B

Nassal, M. (2015) · Gut · doi:10.1136/gutjnl-2015-309809 · Cited by 906 · see citing works

Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo

Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876 · see citing works

The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo

Lin, S.-R., Yang, H.-C., Kuo, Y.-T., Liu, C.-J., Yang, T.-Y., Sung, K.-C., Lin, Y.-Y., Wang, H.-Y., Wang, C.-C., Shen, Y.-C., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.38 · Cited by 386 · see citing works

Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection

Yang, P. L., Althage, A., Chung, J., & Chisari, F. V. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202398599 · Cited by 381 · see citing works

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

Ramanan, V., Shlomai, A., Cox, D. B. T., Schwartz, R. E., Michailidis, E., Bhatta, A., Scott, D. A., Zhang, F., Rice, C. M., & Bhatia, S. N. (2015) · Scientific Reports · doi:10.1038/srep10833 · Cited by 306 · see citing works

An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo

Li, B., Luo, X., Deng, B., Wang, J., McComb, D. W., Shi, Y., Gaensler, K. M. L., Tan, X., Dunn, A. L., Kerlin, B. A., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03528 · Cited by 261 · see citing works

Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication

Dong, C., Qu, L., Wang, H., Wei, L., Dong, Y., & Xiong, S. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.03.015 · Cited by 245 · see citing works

Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus

Zhen, S. M., Hua, L., Liu, Y.-H., Gao, L.-C., Fu, J., Wan, D.-Y., Dong, L.-H., Song, H.-F., & Gao, X. (2015) · Gene Therapy · doi:10.1038/gt.2015.2 · Cited by 233 · see citing works

HBVdb: a knowledge database for Hepatitis B Virus

Hayer, J., Jadeau, F., Deléage, G., Kay, A., Zoulim, F., & Combet, C. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1022 · Cited by 212 · see citing works

Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome

Liu, X., Hao, R., Chen, S., Guo, D., & Chen, Y. Z. (2015) · Journal of General Virology · doi:10.1099/vir.0.000159 · Cited by 151 · see citing works

Recombinant Covalently Closed Circular Hepatitis B Virus DNA Induces Prolonged Viral Persistence in Immunocompetent Mice

Qi, Z., Li, G., Hu, H., Yang, C., Zhang, X., Leng, Q., Xie, Y., Yu, D., Zhang, X., Gao, Y., et al. (2014) · Journal of Virology · doi:10.1128/jvi.01024-14 · Cited by 110 · see citing works

Targeting hepatitis B virus cccDNA using CRISPR/Cas9

Kennedy, E. M., Kornepati, A. V. R., & Cullen, B. R. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.10.004 · Cited by 86 · see citing works

PCSK9 inhibitors and cardiovascular disease

Chapman, M. J., Stock, J. K., & Ginsberg, H. N. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000239 · Cited by 65 · see citing works

Lipid nanoparticles for mRNA delivery

Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076 · see citing works

Drug delivery systems for RNA therapeutics

Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349 · see citing works

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery

Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127 · see citing works

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

Finn, J. D., Smith, A. R., Patel, M. C., Shaw, L., Youniss, M. R., van Heteren, J., Dirstine, T., Ciullo, C., Lescarbeau, R., Seitzer, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.014 · Cited by 878 · see citing works

Tools for translation: non-viral materials for therapeutic mRNA delivery

Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799 · see citing works

CRISPR/Cas9 therapeutics: progress and prospects

Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 770 · see citing works

Exosome–Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs

Lin, Y., Wu, J., Gu, W., Huang, Y., Tong, Z., Huang, L., & Tan, J. (2018) · Advanced Science · doi:10.1002/advs.201700611 · Cited by 625 · see citing works

Therapeutic in vivo delivery of gene editing agents

Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 532 · see citing works

Self-assembled mRNA vaccines

Kim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.014 · Cited by 514 · see citing works

A Comprehensive Review of mRNA Vaccines

Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457 · see citing works

Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities

Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415 · see citing works

The challenge and prospect of mRNA therapeutics landscape

Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417 · see citing works

Thermo-triggered release of CRISPR-Cas9 system by lipid-encapsulated gold nanoparticles for tumor therapy

Wang, P., Zhang, L., Zheng, W., Cong, L., Guo, Z., Xie, Y., Wang, L., Tang, R., Feng, Q., Hamada, Y., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201708689 · Cited by 410 · see citing works

Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3

Qiu, M., Glass, Z., Chen, J., Haas, M., Jin, X., Zhao, X., Rui, X., Ye, Z., Li, Y., Zhang, F., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020401118 · Cited by 419 · see citing works

Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles

Liu, J., Chang, J., Jiang, Y., Meng, X., Sun, T., Mao, L., Xu, Q., & Wang, M. (2019) · Advanced Materials · doi:10.1002/adma.201902575 · Cited by 373 · see citing works

Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery

Maeki, M., Uno, S., Niwa, A., Okada, Y., & Tokeshi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.017 · Cited by 349 · see citing works

Engineering the delivery system for CRISPR-based genome editing

Glass, Z., Lee, M., Li, Y., & Xu, Q. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.11.006 · Cited by 345 · see citing works

CRISPR/Cas9 for cancer research and therapy

Zhan, T., Rindtorff, N., Betge, J., Ebert, M., & Boutros, M. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.001 · Cited by 333 · see citing works

High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing

Sago, C. D., Lokugamage, M. P., Paunovska, K., Vanover, D. A., Monaco, C. M., Shah, N. N., Gamboa Castro, M., Anderson, S. E., Rudoltz, T. G., Lando, G. N., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811276115 · Cited by 313 · see citing works

Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes <i>p53</i> -deficient cancers to mTOR inhibition

Kong, N., Tao, W., Ling, X., Wang, J., Xiao, Y., Shi, S., Ji, X., Shajii, A., Gan, S. T., Kim, N. Y., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1565 · Cited by 314 · see citing works

Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice

Kenjo, E., Hozumi, H., Makita, Y., Iwabuchi, K. A., Fujimoto, N., Matsumoto, S., Kimura, M., Amano, Y., Ifuku, M., Naoe, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26714-w · Cited by 305 · see citing works

Targeted Delivery of CRISPR/Cas9‐Mediated Cancer Gene Therapy via Liposome‐Templated Hydrogel Nanoparticles

Chen, Z., Liu, F., Chen, Y., Liu, J., Wang, X., Chen, A. T., Deng, G., Zhang, H., Liu, J., Hong, Z., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201703036 · Cited by 297 · see citing works

CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases

Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S., & Chakraborty, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.028 · Cited by 295 · see citing works

In vivo gene delivery mediated by non-viral vectors for cancer therapy

Mohammadinejad, R., Dehshahri, A., Madamsetty, V. S., Zahmatkeshan, M., Tavakol, S., Makvandi, P., Khorsandi, D., Pardakhty, A., Ashrafizadeh, M., Afshar, E. G., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.038 · Cited by 238 · see citing works

Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles

Luo, Y., Xu, C., Li, H., Cao, Z., Liu, J., Wang, J., Du, X., Yang, X., Gu, Z., & Wang, J. (2018) · ACS Nano · doi:10.1021/acsnano.7b07874 · Cited by 223 · see citing works

Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma

Liang, C., Li, F., Wang, L., Zhang, Z., Wang, C., He, B., Li, J., Chen, Z., Shaikh, A. B., Liu, J., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.015 · Cited by 216 · see citing works

Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid via a Gold Nanocluster/Lipid Core–Shell Nanocarrier

Wang, P., Zhang, L., Xie, Y., Wang, N., Tang, R., Zheng, W., & Jiang, X. (2017) · Advanced Science · doi:10.1002/advs.201700175 · Cited by 213 · see citing works

Engineered materials for in vivo delivery of genome-editing machinery

Tong, S., Moyo, B., Lee, C. M., Leong, K. W., & Bao, G. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0145-9 · Cited by 206 · see citing works

Nanoparticles Containing Oxidized Cholesterol Deliver mRNA to the Liver Microenvironment at Clinically Relevant Doses

Paunovska, K., Da Silva Sanchez, A. J., Sago, C. D., Gan, Z., Lokugamage, M. P., Islam, F. Z., Kalathoor, S., Krupczak, B. R., & Dahlman, J. E. (2019) · Advanced Materials · doi:10.1002/adma.201807748 · Cited by 205 · see citing works

Strategies for nonviral nanoparticle‐based delivery of CRISPR/Cas9 therapeutics

Chen, F., Alphonse, M., & Liu, Q. (2020) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1609 · Cited by 197 · see citing works

Role of Lipid-Based and Polymer-Based Non-Viral Vectors in Nucleic Acid Delivery for Next-Generation Gene Therapy

Wahane, A. V., Waghmode, A., Kapphahn, A., Dhuri, K., Gupta, A., & Bahal, R. (2020) · Molecules · doi:10.3390/molecules25122866 · Cited by 196 · see citing works

Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases

Xu, C., Lu, Z.-D., Luo, Y., Liu, Y., Cao, Z., Shen, S., Li, H., Liu, J., Chen, K., Chen, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06522-5 · Cited by 198 · see citing works

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside

Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187 · see citing works

Rational designs of in vivo CRISPR-Cas delivery systems

Xu, C., Chen, G., Luo, Y., Zhang, Y., Zhao, G., Lu, Z.-D., Czarna, A., Gu, Z., & Wang, J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.005 · Cited by 185 · see citing works

Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing

Zhang, X., Zhao, W., Nguyen, G. N., Zhang, C., Zeng, C., Yan, J., Du, S., Hou, X., Li, W., Jiang, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc2315 · Cited by 183 · see citing works

An engineered exosome for delivering sgRNA:Cas9 ribonucleoprotein complex and genome editing in recipient cells

Ye, Y., Zhang, X., Xie, F., Xu, B., Xie, P., Yang, T., Shi, Q., Zhang, C., Zhang, Y., Chen, J., et al. (2020) · Biomaterials Science · doi:10.1039/d0bm00427h · Cited by 183 · see citing works

Drug delivery systems for CRISPR-based genome editors

Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 180 · see citing works

Non-liver mRNA Delivery

Loughrey, D., & Dahlman, J. E. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00601 · Cited by 173 · see citing works

Nanoscale platforms for messenger RNA delivery

Li, B., Zhang, X., & Dong, Y. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1530 · Cited by 170 · see citing works

Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing

Rouet, R., Thuma, B. A., Roy, M. D., Lintner, N. G., Rubitski, D. M., Finley, J. E., Wisniewska, H. M., Mendonsa, R., Hirsh, A., de Oñate, L., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01551 · Cited by 163 · see citing works

Analyzing 2000 <i>in Vivo</i> Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery

Paunovska, K., Gil, C. J., Lokugamage, M. P., Sago, C. D., Sato, M., Lando, G. N., Gamboa Castro, M., Bryksin, A. V., & Dahlman, J. E. (2018) · ACS Nano · doi:10.1021/acsnano.8b03640 · Cited by 160 · see citing works

Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy

Han, X., Alu, A., Liu, H., Shi, Y., Wei, X., Cai, L., & Wei, Y. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.01.011 · Cited by 159 · see citing works

CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research

Yang, Y., Xu, J., Ge, S., & Lai, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.649896 · Cited by 160 · see citing works

Triple‐Targeting Delivery of CRISPR/Cas9 To Reduce the Risk of Cardiovascular Diseases

Zhang, L., Wang, L., Xie, Y., Wang, P., Deng, S., Qin, A., Zhang, J., Yu, X., Zheng, W., & Jiang, X. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201903618 · Cited by 144 · see citing works

A Potent Branched-Tail Lipid Nanoparticle Enables Multiplexed mRNA Delivery and Gene Editing In Vivo

Hajj, K. A., Melamed, J. R., Chaudhary, N., Lamson, N. G., Ball, R. L., Yerneni, S. S., & Whitehead, K. A. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c00596 · Cited by 147 · see citing works

Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP

Lin, Y., Wagner, E., & Lächelt, U. (2022) · Biomaterials Science · doi:10.1039/d1bm01658j · Cited by 141 · see citing works

Nanomedicine-Based Approaches for mRNA Delivery

Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139 · see citing works

Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for In Vivo CRISPR/Cas-Based Genome Editing

Wei, T., Cheng, Q., Farbiak, L., Anderson, D. G., Langer, R., & Siegwart, D. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c04707 · Cited by 137 · see citing works

Nanomaterials for Therapeutic RNA Delivery

Han, X., Mitchell, M. J., & Nie, G. (2020) · Matter · doi:10.1016/j.matt.2020.09.020 · Cited by 137 · see citing works

Nanoplatforms for mRNA Therapeutics

Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130 · see citing works

Biomedical applications of mRNA nanomedicine

Xiong, Q., Lee, G. Y., Ding, J., Li, W., & Shi, J. (2018) · Nano Research · doi:10.1007/s12274-018-2146-1 · Cited by 125 · see citing works

mRNA therapeutics deliver a hopeful message

Zhong, Z., Cafferty, S. M., Combes, F., Huysmans, H., Temmerman, J. D., Gitsels, A., Vanrompay, D. C. G., Catani, J. P., & Sanders, N. N. (2018) · Nano Today · doi:10.1016/j.nantod.2018.10.005 · Cited by 120 · see citing works

Material solutions for delivery of CRISPR/Cas-based genome editing tools: Current status and future outlook

Wan, T. Y., Niu, D., Wu, C., Xu, F., Church, G. M., & Yuan, P. (2019) · Materials Today · doi:10.1016/j.mattod.2018.12.003 · Cited by 118 · see citing works

CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects

Zhang, Z., Zhang, Y., Gao, F., Han, S., Cheah, K. S. E., Tse, H., & Lian, Q. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.09.009 · Cited by 116 · see citing works

Non-Viral Delivery To Enable Genome Editing

Rui, Y., Wilson, D. R., & Green, J. J. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.08.010 · Cited by 115 · see citing works

Systemic mRNA delivery to the lungs by functional polyester-based carriers

Yan, Y., Xiong, H., Zhang, X., Cheng, Q., & Siegwart, D. J. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b01356 · Cited by 111 · see citing works

Carrier strategies boost the application of CRISPR/Cas system in gene therapy

Xu, Z., Wang, Q., Zhong, H., Jiang, Y., Shi, X., Yuan, B., Yu, N., Zhang, S., Yuan, X., Guo, S., et al. (2022) · Exploration · doi:10.1002/exp.20210081 · Cited by 104 · see citing works

Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies

Xu, Q., Zhang, Z., Zhao, L., Qin, Y., Cai, H., Geng, Z., Zhu, X., Zhang, W., Zhang, Y., Tan, J., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.033 · Cited by 103 · see citing works

Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methods.

Mashel, T., Tarakanchikova, Y., Muslimov, A., Zyuzin, M., Timin, A., Lepik, K., & Fehse, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120282 · Cited by 92 · see citing works

Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease

Ernst, M. P. T., Broeders, M., Herrero-Hernandez, P., Oussoren, E., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.022 · Cited by 99 · see citing works

Targeted delivery of CRISPR interference system against Fabp4 to white adipocytes ameliorates obesity, inflammation, hepatic steatosis, and insulin resistancePreprint

Chung, J. Y., Ain, Q. U., Song, Y., Yong, S., & Kim, Y. (2019) · Genome Research · doi:10.1101/gr.246900.118 · Cited by 101 · see citing works

Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid

Tang, Q., Liu, J., Jiang, Y. Y., Zhang, M., Mao, L., & Wang, M. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b17749 · Cited by 98 · see citing works

GMOs or non-GMOs? The CRISPR Conundrum

Ahmad, A., Jamil, A., & Munawar, N. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1232938 · Cited by 106 · see citing works

Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets

Conway, A., Mendel, M., Kim, K., McGovern, K., Boyko, A., Zhang, L., Miller, J. C., DeKelver, R. C., Paschon, D. E., Mui, B. L., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.003 · Cited by 95 · see citing works

Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy

Zhang, C., Ma, Y., Zhang, J., Kuo, J. C., Zhang, Z., Xie, H., Zhu, J., & Liu, T. (2022) · Molecules · doi:10.3390/molecules27061943 · Cited by 93 · see citing works

Next-Generation CRISPR Technologies and Their Applications in Gene and Cell Therapy

C., M. A. Z., & Gaj, T. (2020) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.10.010 · Cited by 94 · see citing works

The Promise and Challenge of In Vivo Delivery for Genome Therapeutics

Wilson, R. C., & Gilbert, L. A. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00680 · Cited by 92 · see citing works

Theranostic dendrimer-based lipid nanoparticles containing PEGylated BODIPY dyes for tumor imaging and systemic mRNA delivery in vivo

Xiong, H., Liu, S., Wei, T., Cheng, Q., & Siegwart, D. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.030 · Cited by 64 · see citing works

Engineering nanoparticle toolkits for mRNA delivery

Sun, B. F., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 93 · see citing works

Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: Advances in genome editing and CAR T cell therapy

Soroudi, S., Jaafari, M. R., & Arabi, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.023 · Cited by 91 · see citing works

Biomaterials as vectors for the delivery of CRISPR–Cas9

Eoh, J. H., & Gu, L. (2019) · Biomaterials Science · doi:10.1039/c8bm01310a · Cited by 91 · see citing works

Design concepts of polyplex micelles for in vivo therapeutic delivery of plasmid DNA and messenger RNA

Uchida, S., & Kataoka, K. (2019) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36614 · Cited by 90 · see citing works

Lipid Polymer Hybrid Nanomaterials for mRNA Delivery

Zhao, W., Zhang, C., Li, B., Zhang, X., Luo, X. L., Zeng, C., Li, W., Gao, M., & Dong, Y. (2018) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-018-0536-9 · Cited by 85 · see citing works

Testing thousands of nanoparticles in vivo using DNA barcodes

Lokugamage, M. P., Sago, C. D., & Dahlman, J. E. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.08.001 · Cited by 81 · see citing works

Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli‐Responsive Vehicles

Cai, W., Luo, T., Mao, L., & Wang, M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005644 · Cited by 83 · see citing works

RNA delivery biomaterials for the treatment of genetic and rare diseases

Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82 · see citing works

Harnessing nanoparticles for the efficient delivery of the CRISPR/Cas9 system

Rahimi, H., Salehiabar, M., Charmi, J., Barsbay, M., Ghaffarlou, M., Razlighi, M. R., Davaran, S., Khalilov, R. I., Sugiyama, M., Nosrati, H., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100895 · Cited by 83 · see citing works

Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing

Sinclair, F., Begum, A. A., Dai, C. C., Tóth, I., & Moyle, P. M. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01320-z · Cited by 88 · see citing works

Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma

Kong, H., Ju, E., Yi, K., Xu, W., Lao, Y., Cheng, D., Zhang, Q., Tao, Y., Li, M., & Ding, J. (2021) · Advanced Science · doi:10.1002/advs.202102051 · Cited by 76 · see citing works

CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting: Nanomaterials and Translational Perspective

Sahel, D. K., Vora, L. K., Saraswat, A. L., Sharma, S., Monpara, J. D., D’souza, A. A., Mishra, D., Tryphena, K. P., Kawakita, S., Khan, S. U., et al. (2023) · Advanced Science · doi:10.1002/advs.202207512 · Cited by 76 · see citing works

An antifouling membrane-fusogenic liposome for effective intracellular delivery in vivo

Kong, H., Zheng, C., Yi, K., Mintz, R. L., Lao, Y., Tao, Y., & Li, M. (2024) · Nature Communications · doi:10.1038/s41467-024-46533-z · Cited by 77 · see citing works

Small molecules as inhibitors of PCSK9: Current status and future challenges

Xu, S., Luo, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.011 · Cited by 85 · see citing works

Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing

Tang, H., Zhao, X., & Jiang, X. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.03.001 · Cited by 76 · see citing works

Fluorinated Acid‐Labile Branched Hydroxyl‐Rich Nanosystems for Flexible and Robust Delivery of Plasmids

Yu, Q., Song, H., Xiao, H., Cheng, G., Yu, B., & Xu, F. (2018) · Small · doi:10.1002/smll.201803061 · Cited by 75 · see citing works

Gene Therapy for Chronic HBV—Can We Eliminate cccDNA?

Bloom, K. M., Maepa, M. B., Ely, A., & Arbuthnot, P. B. (2018) · Genes · doi:10.3390/genes9040207 · Cited by 74 · see citing works

Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes

Veiga, N., Diesendruck, Y., & Peer, D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.002 · Cited by 74 · see citing works

Augmented lipid-nanoparticle-mediated in vivo genome editing in the lungs and spleen by disrupting Cas9 activity in the liver

Sago, C. D., Lokugamage, M. P., Loughrey, D., Lindsay, K. E., Hincapie, R., Krupczak, B. R., Kalathoor, S., Sato, M., Echeverri, E. S., Fitzgerald, J. P., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00847-9 · Cited by 74 · see citing works

Poly(Beta-Amino Ester) Nanoparticles Enable Nonviral Delivery of CRISPR-Cas9 Plasmids for Gene Knockout and Gene Deletion

Rui, Y., Varanasi, M., Mendes, S., Yamagata, H. M., Wilson, D. R., & Green, J. J. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.04.005 · Cited by 70 · see citing works

Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus

Liu, Y., Zhao, M., Gong, M., Xu, Y., Xie, C., Deng, H., Li, X., Wu, H., & Wang, Z. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.02.011 · Cited by 71 · see citing works

A Dual-Targeting Delivery System for Effective Genome Editing and In Situ Detecting Related Protein Expression in Edited Cells

Liu, B., He, X., Xu, C., Xu, L., Ai, S., Cheng, S., & Zhuo, R. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00511 · Cited by 68 · see citing works

Nanotechnology based CRISPR/Cas9 system delivery for genome editing: Progress and prospect

Deng, H., Huang, W., & Zhang, Z. (2019) · Nano Research · doi:10.1007/s12274-019-2465-x · Cited by 69 · see citing works

Harnessing lipid nanoparticles for efficient CRISPR delivery

Yan, J., Kang, D. D., & Dong, Y. (2021) · Biomaterials Science · doi:10.1039/d1bm00537e · Cited by 68 · see citing works

Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections

Najafi, S., Tan, S. C., Aghamiri, S., Raee, P., Ebrahimi, Z., Jahromi, Z. K., Rahmati, Y., Nahand, J. S., Piroozmand, A., Jajarmi, V., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112743 · Cited by 68 · see citing works

Evolving AAV-delivered therapeutics towards ultimate cures

He, X., Urip, B. A., Zhang, Z., Ngan, C. C., & Feng, B. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02034-2 · Cited by 67 · see citing works

CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges

Demirci, S., Leonard, A. K., Haro‐Mora, J. J., Uchida, N., & Tisdale, J. F. (2019) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_331 · Cited by 67 · see citing works

Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy

Yi, K., Kong, H., Lao, Y., Li, D., Mintz, R. L., Fang, T., Chen, G., Tao, Y., Li, M., & Ding, J. (2023) · Advanced Materials · doi:10.1002/adma.202300665 · Cited by 65 · see citing works

Proteomic profiling of HIV-1 infection of human CD4+ T cells identifies PSGL-1 as an HIV restriction factor

Liu, Y., Fu, Y., Wang, Q., Li, M., Zhou, Z., Dabbagh, D., Fu, C., Zhang, H., Li, S., Zhang, T., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0372-2 · Cited by 63 · see citing works

Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy

Wang, L., Zheng, W., Liu, S., Li, B. J., & Jiang, X. (2018) · ChemBioChem · doi:10.1002/cbic.201800629 · Cited by 65 · see citing works

Non-viral strategies for delivering genome editing enzymes

Li, J., Røise, J. J., He, M., Das, R., & Murthy, N. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.004 · Cited by 63 · see citing works

Spatial and Temporal Control of CRISPR-Cas9-Mediated Gene Editing Delivered via a Light-Triggered Liposome System

Aksoy, Y. A., Yang, B., Chen, W., Hung, T., Kuchel, R. P., Zammit, N. W., Grey, S. T., Goldys, E. M., & Deng, W. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c16380 · Cited by 62 · see citing works

Optimization of lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes for in vivo delivery of a CRISPR/Cas9 system targeting hepatitis B virus

Akhter, R., Kitab, B., Kayesh, M. E. H., Shimizu, R., Onuma, H., Yamamoto, N., Ogawa, S., Sugiyama, M., Tanaka, Y., Sato, Y., et al. (2025) · Virus Research · doi:10.1016/j.virusres.2025.199682 · Cited by 1 · see citing works

Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA

Kayesh, M. E. H., Amako, Y., Hashem, M. A., Murakami, S., Ogawa, S., Yamamoto, N., Hifumi, T., Miyoshi, N., Sugiyama, M., Tanaka, Y., et al. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198191 · Cited by 37 · see citing works

In vivo Delivery Tools for Clustered Regularly Interspaced Short Palindromic Repeat/Associated Protein 9-Mediated Inhibition of Hepatitis B Virus Infection: An Update

Kayesh, M. E. H., Hashem, M. A., Kohara, M., & Tsukiyama–Kohara, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.953218 · Cited by 4 · see citing works

Preparation of nanoparticles for hepatitis B viral therapy

Kružíková, Z. (2018) · Digital Repository (National Repository of Grey Literature)

CRISPR-Cas9 System In Vivo Delivery to Combat HBV

Ali, J., Aslam, H., & Yousuf, A. (2023) · BIOEDUSCIENCE · doi:10.22236/jbes/12693 · Cited by 1 · see citing works